Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI

• Status: Completed
• Trial end date: 2017-12-26
• Target enrollment: 0
• Participant gender: All

Summary

Platelets and thrombus formation play a key role in the pathogenesis of acute coronary artery occlusion and subsequent myocardial infarction. Apart from mechanically opening the occluded artery with angioplasty, adjunctive antiplatelet treatment is of utmost importance. However, orally administered antiplatelet agents exhibit a delay in their onset of action in the setting of acute myocardial infarction and angioplasty is mostly performed without adequate platelet inhibition. Cangrelor is an intravenous antiplatelet agent which can provide almost immediate strong platelet inhibition. The investigators aim to compare a strategy of cangrelor administered on top of ticagrelor-an oral antiplatelet agent- vs ticagrelor alone, on their efficacy to inhibit platelet function in the early hours of an acute myocardial infarction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Attikon Hospital
• Collaborators: AHEPA University Hospital; University Hospital, Alexandroupolis
• Treatments: Cangrelor; Ticagrelor

Criteria

Inclusion Criteria:

• Consecutive P2Y12 inhibitor-naive STEMI patients with pain onset<12 hours admitted for primary PCI.

Exclusion Criteria:

• a history of stroke/transient ischemic attack

• bleeding diathesis

• chronic oral anticoagulation treatment

• contraindications to anti platelet therapy

• PCI or coronary artery bypass grafting <3 months

• platelet count <100 000/μL

• hematocrit <30%

• creatinine clearance <30 mL/min

• severe hepatic dysfunction

• use of strong CYP3A inhibitors or inducers

• increased risk of bradycardia

• severe chronic obstructive pulmonary disease

• periprocedural IIb/IIIa inhibitor administration.